XML 22 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Net income $ 125.3 $ 594.8
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation and amortization 44.0 19.4
Equity-based compensation 54.4 39.7
Non-cash performance allocations and incentive fees, net (36.7) (300.8)
Non-cash principal investment income (7.7) (315.3)
Other non-cash amounts 10.8 5.3
Consolidated Funds related:    
Realized/unrealized (gain) loss on investments of Consolidated Funds (145.0) 43.4
Realized/unrealized (gain) loss from loans payable of Consolidated Funds 141.4 (46.2)
Purchases of investments by Consolidated Funds (386.6) (1,025.9)
Proceeds from sale and settlements of investments by Consolidated Funds 332.5 1,113.7
Non-cash interest income, net (3.7) (2.7)
Change in cash and cash equivalents held at Consolidated Funds (20.8) (21.1)
Change in other receivables held at Consolidated Funds 7.1 (6.0)
Change in other liabilities held at Consolidated Funds (32.8) (34.1)
Purchases of investments (18.5) (307.5)
Proceeds from the sale of investments 78.6 158.3
Payments of contingent consideration (68.6) (5.7)
Changes in deferred taxes, net (15.1) 110.9
Change in due from affiliates and other receivables 16.9 (9.5)
Change in deposits and other (33.9) (39.8)
Change in accounts payable, accrued expenses and other liabilities (63.9) (14.3)
Change in accrued compensation and benefits (371.9) (580.1)
Change in due to affiliates (0.2) (0.2)
Change in lease right-of-use assets and lease liabilities (2.8) (2.5)
Change in deferred revenue 284.7 254.5
Net cash used in operating activities (112.5) (371.7)
Cash flows from investing activities    
Purchases of corporate treasury investments (101.1) 0.0
Proceeds from corporate treasury investments 20.1 0.0
Purchases of fixed assets, net (12.9) (12.3)
Purchase of CBAM intangibles and investments, net 0.0 (618.4)
Net cash used in investing activities (93.9) (630.7)
Cash flows from financing activities    
Payments on CLO borrowings (1.1) (8.9)
Proceeds from CLO borrowings, net of financing costs 0.0 40.8
Net borrowings (payments) on loans payable of Consolidated Funds 68.7 (21.8)
Dividends to common stockholders (118.4) (89.5)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)
Contributions from non-controlling interest holders 18.7 146.8
Distributions to non-controlling interest holders (9.9) (147.1)
Common shares issued for performance allocations 0.0 31.3
Common shares repurchased (100.3) (80.4)
Change in due to/from affiliates financing activities 74.6 33.1
Net cash used in financing activities (136.5) (164.5)
Effect of foreign exchange rate changes 8.3 (17.4)
Decrease in cash, cash equivalents and restricted cash (334.6) (1,184.3)
Cash, cash equivalents and restricted cash, beginning of period 1,361.5 2,475.1
Cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8
Reconciliation of cash, cash equivalents and restricted cash, end of period:    
Cash and cash equivalents 1,010.1 1,290.2
Restricted cash 16.8 0.6
Total cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8
Cash and cash equivalents held at Consolidated Funds 228.8 168.9
Consolidated Operating Entities    
Cash flows from operating activities    
Net income 108.1 569.7
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation and amortization 44.0 19.4
Equity-based compensation 54.4 39.7
Non-cash performance allocations and incentive fees, net (38.2) (300.8)
Non-cash principal investment income (8.7) (295.4)
Other non-cash amounts 10.8 5.3
Consolidated Funds related:    
Purchases of investments (19.0) (294.1)
Proceeds from the sale of investments 78.9 169.5
Payments of contingent consideration (68.6) (5.7)
Changes in deferred taxes, net (15.1) 110.9
Change in due from affiliates and other receivables 17.0 (8.8)
Change in deposits and other (33.9) (39.8)
Change in accounts payable, accrued expenses and other liabilities (63.9) (14.3)
Change in accrued compensation and benefits (371.9) (580.1)
Change in due to affiliates (0.2) (0.2)
Change in lease right-of-use assets and lease liabilities (2.8) (2.5)
Change in deferred revenue 284.7 254.5
Net cash used in operating activities (24.4) (372.7)
Cash flows from investing activities    
Purchases of corporate treasury investments (101.1) 0.0
Purchases of fixed assets, net (12.9) (12.3)
Purchase of CBAM intangibles and investments, net 0.0 (618.4)
Net cash used in investing activities (93.9) (630.7)
Cash flows from financing activities    
Payments on CLO borrowings (1.1) (8.9)
Proceeds from CLO borrowings, net of financing costs 0.0 40.8
Dividends to common stockholders (118.4) (89.5)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)
Contributions from non-controlling interest holders 2.0 5.8
Distributions to non-controlling interest holders (8.5) (27.1)
Common shares issued for performance allocations 0.0 31.3
Common shares repurchased (100.3) (80.4)
Change in due to/from affiliates financing activities 73.0 33.1
Net cash used in financing activities (222.1) (163.7)
Effect of foreign exchange rate changes 5.8 (17.2)
Decrease in cash, cash equivalents and restricted cash (334.6) (1,184.3)
Cash, cash equivalents and restricted cash, beginning of period 1,361.5 2,475.1
Cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8
Supplemental non-cash disclosures    
Issuance of common shares related to the acquisition of CBAM 0.0 194.5
Reconciliation of cash, cash equivalents and restricted cash, end of period:    
Cash and cash equivalents 1,010.1 1,290.2
Restricted cash 16.8 0.6
Total cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8
Cash and cash equivalents held at Consolidated Funds 228.8 168.9
Consolidated Operating Entities | MRE    
Cash flows from investing activities    
Proceeds from corporate treasury investments $ 20.1 $ 0.0